Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 2
2007 2
2008 6
2009 2
2010 5
2011 5
2012 5
2013 11
2014 7
2015 8
2016 14
2017 9
2018 8
2019 12
2020 10
2021 22
Text availability
Article attribute
Article type
Publication date

Search Results

105 results
Results by year
Filters applied: . Clear all
Page 1
Cancer immunotherapies targeting the PD-1 signaling pathway.
Iwai Y, Hamanishi J, Chamoto K, Honjo T. Iwai Y, et al. Among authors: hamanishi j. J Biomed Sci. 2017 Apr 4;24(1):26. doi: 10.1186/s12929-017-0329-9. J Biomed Sci. 2017. PMID: 28376884 Free PMC article. Review.
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I. Hamanishi J, et al. Int J Clin Oncol. 2016 Jun;21(3):462-73. doi: 10.1007/s10147-016-0959-z. Epub 2016 Feb 22. Int J Clin Oncol. 2016. PMID: 26899259 Free PMC article. Review.
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.
Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W. Lin H, et al. Among authors: hamanishi j. J Clin Invest. 2018 Feb 1;128(2):805-815. doi: 10.1172/JCI96113. Epub 2018 Jan 16. J Clin Invest. 2018. PMID: 29337305 Free PMC article.
VISTA expressed in tumour cells regulates T cell function.
Mulati K, Hamanishi J, Matsumura N, Chamoto K, Mise N, Abiko K, Baba T, Yamaguchi K, Horikawa N, Murakami R, Taki M, Budiman K, Zeng X, Hosoe Y, Azuma M, Konishi I, Mandai M. Mulati K, et al. Among authors: hamanishi j. Br J Cancer. 2019 Jan;120(1):115-127. doi: 10.1038/s41416-018-0313-5. Epub 2018 Nov 9. Br J Cancer. 2019. PMID: 30382166 Free PMC article.
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, Matsumura N, Abiko K, Baba T, Yamaguchi K, Ueda A, Hosoe Y, Morita S, Yokode M, Shimizu A, Honjo T, Konishi I. Hamanishi J, et al. J Clin Oncol. 2015 Dec 1;33(34):4015-22. doi: 10.1200/JCO.2015.62.3397. Epub 2015 Sep 8. J Clin Oncol. 2015. PMID: 26351349 Clinical Trial.
Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer.
Peng J, Hamanishi J, Matsumura N, Abiko K, Murat K, Baba T, Yamaguchi K, Horikawa N, Hosoe Y, Murphy SK, Konishi I, Mandai M. Peng J, et al. Among authors: hamanishi j. Cancer Res. 2015 Dec 1;75(23):5034-45. doi: 10.1158/0008-5472.CAN-14-3098. Epub 2015 Nov 16. Cancer Res. 2015. PMID: 26573793 Free article.
Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer.
Okamoto A, Kondo E, Nakamura T, Yanagida S, Hamanishi J, Harano K, Hasegawa K, Hirasawa T, Hori K, Komiyama S, Matsuura M, Nakai H, Nakamura H, Sakata J, Tabata T, Takehara K, Takekuma M, Yokoyama Y, Kase Y, Sumino S, Soeda J, Suri A, Aoki D, Sugiyama T. Okamoto A, et al. Among authors: hamanishi j. J Gynecol Oncol. 2021 Mar;32(2):e16. doi: 10.3802/jgo.2021.32.e16. Epub 2020 Dec 10. J Gynecol Oncol. 2021. PMID: 33327047 Free PMC article. Clinical Trial.
Immune checkpoint inhibition in ovarian cancer.
Hamanishi J, Mandai M, Konishi I. Hamanishi J, et al. Int Immunol. 2016 Jul;28(7):339-48. doi: 10.1093/intimm/dxw020. Epub 2016 Apr 7. Int Immunol. 2016. PMID: 27055470 Review.
105 results